ideasIdea
A test to tell true oligometastatic disease from hidden widespread spread
Some people have only a few spots of spread and can be cured by treating each one. Others have many spots not yet visible. A test to tell them apart would spare futile treatment and find curable patients.
Ablative treatment of all visible lesions improves survival in selected patients, but selection today is anatomical and therefore crude. Candidate discriminators include ctDNA level and clearance kinetics, microRNA classifiers reported in oligometastatic lung cancer, and clonal diversity across lesions. A locked signature, prospectively validated, would define the biology rather than the lesion count.
Hypothesis
A combined ctDNA-kinetic and transcriptomic signature identifies patients whose disease is genuinely restricted, in whom total metastasis-directed ablation gives two-year progression-free survival above 50%, against below 20% in signature-negative patients.
Rationale
The benefit of metastasis-directed therapy varies enormously and unpredictably, which is the signature of a mixed population. Analogous molecular refinement transformed adjuvant chemotherapy decisions in breast cancer through genomic assays.
What would test it
Embed a locked biomarker panel in an ongoing metastasis-directed radiotherapy trial with a pre-specified interaction analysis; a null interaction kills the signature cheaply.
Maturity
early clinical
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.